CLINICAL TRIALS PROFILE FOR PARDOPRUNOX

Clinical Trials for Pardoprunox

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00269516 ↗	SLV308 for Treatment of Patients With Early Parkinson's Disease	Completed	Solvay Pharmaceuticals	Phase 3	This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
NCT00332917 ↗	An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients	Completed	Solvay Pharmaceuticals	Phase 3	This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
NCT00335374 ↗	An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients	Completed	Solvay Pharmaceuticals	Phase 3	This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
NCT00406588 ↗	SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations	Completed	Solvay Pharmaceuticals	Phase 3	This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
NCT00407095 ↗	An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.	Completed	Solvay Pharmaceuticals	Phase 3	This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.
NCT00903838 ↗	A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.	Terminated	Abbott Products	Phase 2	This is a multicenter, randomized, double blind, pramipexole-controlled parallel group study of pardoprunox as adjunctive treatment to levodopa.

Clinical Trial Conditions for Pardoprunox

Condition Name

Condition Name
Intervention	Trials
Advanced Stage Parkinson's Disease	3
Early Stage Parkinson's Disease	3

Condition MeSH

Condition MeSH
Intervention	Trials
Parkinson Disease	6
Dyskinesias	1

Clinical Trial Locations for Pardoprunox

Trials by Country

Trials by Country
Location	Trials
United States	65
Russian Federation	4
Chile	4
Argentina	4
Canada	4

Trials by US State

Trials by US State
Location	Trials
Ohio	5
North Carolina	5
Florida	5
California	5
Missouri	4

Clinical Trial Progress for Pardoprunox

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	5
Phase 2	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	5
Terminated	1

Clinical Trial Sponsors for Pardoprunox

Sponsor Name

Sponsor Name
Sponsor	Trials
Solvay Pharmaceuticals	5
Abbott Products	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	6